Company Overview of Afferent Pharmaceuticals, Inc.
Afferent Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops small molecule compounds that target P2X3 receptors for the treatment of chronic pain, respiratory, and urological conditions. Its products include AF-219 that is used for patients with osteoarthritis pain, treatment-refractory chronic cough, and interstitial cystitis/bladder pain syndrome; and AF-220, a second-generation P2X3 antagonist. The company was founded in 2009 and is based in San Mateo, California.
2929 Campus Drive
San Mateo, CA 94403
Founded in 2009
Key Executives for Afferent Pharmaceuticals, Inc.
Co-Founder and Chief Scientific Officer
Vice President of Clinical Operations
Vice President of Regulatory Affairs and Project Management
Compensation as of Fiscal Year 2015.
Afferent Pharmaceuticals, Inc. Key Developments
Afferent Pharmaceuticals Announces Executive Appointments
Nov 19 15
Afferent Pharmaceuticals announced the appointments of Prabha N. Ibrahim, Ph.D., as chief technology officer and Michelle Carpenter, J.D., RAC, as vice president of regulatory affairs and project management. Dr. Ibrahim will be responsible for directing manufacturing of drug supplies, from initial scale up to registration and commercial supplies, as well as management of Afferent’s intellectual property portfolio, while Ms. Carpenter will be responsible for global regulatory affairs as well as project management for the company’s development stage programs. Dr. Ibrahim brings more than 23 years of experience in drug discovery and development, having served in a number of senior leadership positions at Plexxikon Inc., most recently as senior vice president of chemistry and non-clinical development. Ms. Carpenter brings 25 years of biopharmaceutical experience in regulatory strategy and operations in support of drug development and commercialization. Prior to joining Afferent, Ms. Carpenter held senior positions at Acucela.
Afferent Pharmaceuticals, Inc. Announces Phase 2 Clinical Trial with AF-219 in Cough in Idiopathic Pulmonary Fibrosis Patients
Nov 11 15
Afferent Pharmaceuticals announced that it has initiated a Phase 2 clinical trial with AF-219 in idiopathic pulmonary fibrosis patients with cough. AF-219 is a selective, non-narcotic and orally administered P2X3 antagonist that targets the mechanism by which certain nerve fibers become hyper-sensitized and can lead to chronic and debilitating symptoms. The study is expected to enroll at least 30 patients at more than 15 sites in the United States, including pulmonary fibrosis specialty treatment centers. The randomized, double-blind, placebo-controlled, crossover study will measure the effect of AF-219 compared to placebo at a dose of 50 mg twice daily for two weeks on cough frequency, as measured objectively by a cough recording device. Following a two-week washout period, patients are then crossed over to the alternate treatment arm and dosed twice daily for an additional two weeks. Cough frequency is measured at each baseline and at the end of each treatment period. The study will also examine the effect of AF-219 on breathlessness, another debilitating symptom from which IPF patients suffer. Idiopathic pulmonary fibrosis is a chronic, irreversible lung disease characterized by scarring of lung tissue, with no known cause. Primary symptoms are cough and shortness of breath. The National Institutes of Health has recently reported the prevalence of IPF in the U.S. is 200,000 patients, making it an orphan indication. Approximately 70-85% of IPF patients suffer from cough. IPF patients are often first diagnosed as a result of their persistent cough. Currently available drug treatments have not been shown to affect IPF patients’ chronic cough or breathlessness, symptoms that significantly impair quality of life and progress as the disease worsens. In addition to the Phase 2 IPF cough trial, Afferent is currently conducting a Phase 2b lower-dose escalation study with AF-219 in chronic cough patients. Top-line data from this study are expected in the first quarter of 2016. Additionally, a 12-week Phase 2b trial with AF-219 in chronic cough in the U.S. and United Kingdom is planned.
Afferent Pharmaceuticals Announces Positive Results in Phase 2b Chronic Cough Trial
Sep 28 15
Afferent Pharmaceuticals, announced positive top-line results from its Phase 2b dose escalation clinical trial of AF-219 in chronic cough patients. AF-219 is a selective, non-narcotic and orally administered P2X3 antagonist that targets the mechanism by which certain nerve fibers become hyper-sensitized and can lead to chronic and debilitating symptoms. The results of this clinical trial will be presented at a scientific meeting in the future. The study randomized 29 chronic cough patients. Doses of 50 mg, 100 mg, 150 mg and 200 mg twice daily for 4 days demonstrated significant reduction in cough frequency, including at the lowest dose of 50 mg twice daily. Cough frequency was measured objectively utilizing a cough recording device, with periodic measurements following AF-219 treatment compared to a baseline recording. All AF-219 doses, including the lowest dose of 50 mg twice daily, demonstrated a statistically significant reduction in awake cough frequency compared to placebo (p=0.002). AF-219 was generally well tolerated. The incidence of decreased taste acuity, as observed in the first study at 600 mg twice daily, was much less at the 50 mg dose. Only one patient discontinued treatment at any dose in the current study, due to the taste effect.
Similar Private Companies By Industry
Recent Private Companies Transactions
July 1, 2015